MindMed has commenced a study for its “LSD neutralizer technology,” which it hopes will be effective in shortening and even stopping the effects of an LSD trip during LSD assisted therapy sessions.
In collaboration with the Liechti Lab at University Hospital Basel, a Phase 1 clinical trial will evaluate the effect of ketanserin for this purpose.
MindMed hopes the study will be completed by the end of 2021.